Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

PRIMO 2023 | Unanswered questions in screening for prostate cancer

Ravi Madan, MD, National Cancer Institute, Bethesda, MD, provides an overview of remaining issues relating to prostate cancer screening. Underdiagnosis in patients may result in an increase of metastatic prostate cancer. There is consequently a need for novel biomarkers in addition to PSA screening. This interview took place at the Practical Recommendations in Immuno and Molecular Oncology (PRIMO) 2023 Congress in Honolulu, HI.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.